Dec. 2, 2022
12/01/2022 07:19 PM EST

Antony J. Blinken, Secretary of State

World AIDS Day reminds us that HIV/AIDS continues to pose a threat to global health and global health security. With 650,000 people having lost their lives to AIDS-related illnesses last year, the United States government remains committed to working with our global partners to end the HIV/AIDS pandemic.

The data released today by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) indicates that we are making steady progress to address the gaps that continue to put people at risk, particularly the most vulnerable populations. Over the nearly 20 years since the program began, PEPFAR has saved 25 million lives. PEPFAR’s success is the result of close to two decades of bipartisan support across presidential administrations and from the U.S. Congress. That unwavering support is evidenced by the more than $100 billion investment in the global fight to end HIV/AIDS through PEPFAR. We will continue our commitment to sustained support of these efforts to help reach the goal of ending AIDS by 2030.

PEPFAR also relies on partnership. Since inception, the program has built global partnerships with multilateral and public-private organizations, communities, governments and the private sector. Together, we have taken the bold action required to protect and advance global HIV/AIDS gains and we will continue our focus on these targeted efforts in the midst of the needs to address other health crises around the world. Since 2020, our effort has included supporting COVID-19 responses in PEPFAR countries by leveraging the robust public health and clinical platforms established by PEPFAR.

This year’s theme for World AIDS Day is “Putting Ourselves to the Test: Achieving Equity to End HIV.” It emphasizes accountability and action and affirms the Administration’s dedication to ending HIV/AIDS, domestically and abroad, through an approach that centers on fighting inequities, advancing equality, and rallying the world to end HIV as a global health threat by 2030.

As we approach the 20th anniversary of PEPFAR, guided by the PEPFAR five-year strategy released today, the United States government will continue to support the global HIV/AIDS response with great determination and in close collaboration with our partners, who share our commitment to saving lives and ending this pandemic.



Jul. 19, 2021
Just a few hours to go until the official opening of IAS 2021 – the 11th IAS Conference on HIV Science. Join thousands of HIV professionals at the world’s most influential virtual meeting on HIV research from 18-21 July.
Register now
Breaking news
Exciting new studies that will be presented at IAS 2021 are already making headlines:
Meet the featured speakers
IAS 2021 will feature an exciting speaker line-up of global health experts highlighting the latest in HIV science.
Meet the speakers
See what to expect at IAS 2021
You can look forward to a wide range of basic, clinical, prevention, social, behavioural and implementation science at IAS 2021. Browse through over 60 sessions, 50 satellite symposia, hundreds of E-posters and dozens of oral abstracts.
View the programme
Join the conversation

Stay up to date and virtually connected by following the official IAS 2021 social media channels.
Copyright © 2021 International AIDS Society, All rights reserved.
You are receiving this email because you provided your email address to the International AIDS Society. Want to receive fewer emails from us? Want to receive conference news only? Update your subscription preferences at the link below.

Our mailing address is:
International AIDS Society
23 Avenue de France
Geneva 1202
Jul. 19, 2021


Jul. 19, 2021

We’re less than two days away from the official opening of IAS 2021 – the 11th IAS Conference on HIV Science. If you have not yet registered as media, it’s not too late to gain full access to the conference – register now! 

In this advisory: 

  • Abstract embargo information 
  • Opening session and panel info, for Sunday, 18 July
  • Updated media summary for Abstract 2585 

Abstract posting and embargoes 

  • All on-demand abstracts and e-posters will be available and their embargo lifts from Saturday, 17 July, at 12:00 (noon) CEST. 
  • Scheduled sessions will start on Sunday, 18 July, at 07:30 CEST.

Don’t miss the official opening of IAS 2021 
The session includes a panel discussion, “From Pandemic to Pandemic”, featuring: 
  • Anthony Fauci, National Institutes of Health, United States 
  • Yvette Raphael, Advocacy for the Prevention of HIV and AIDS, United States 
  • Soumya Swaminathan, World Health Organization, Switzerland 
  • Jens Spahn, Federal Minister of Health, Germany 
Updated media summary: Prevalence of HIV drug resistance in PrEP rollout participants who acquire HIV, Abstract 2585 

The following is an updated summary of Abstract 2585, which is related to the prevalence of HIV drug resistance in PrEP rollout participants who acquire HIV. It was featured in the IAS 2021 official press conference and news release, and has been updated to include new data and information from the author. 

A study from the Global Evaluation of Microbicide Sensitivity (GEMS) project found very low rates of seroconversion among individuals participating in HIV pre-exposure prophylaxis (PrEP) rollout programmes in sub-Saharan Africa. In the small subset of individuals who acquired HIV despite being in a PrEP programme, 23% were found to have HIV with resistance mutations to the antiretroviral drugs used for PrEP. 

The project implemented drug resistance monitoring for PrEP users who were diagnosed with HIV during participation in oral TDF-based PrEP programmes in Eswatini, Kenya, South Africa and Zimbabwe. Of the estimated 104,000 PrEP users, 229 seroconversions were reported and 208 participants provided a sample for the study. Half of participants were 16-24 years of age and three-quarters were female. The majority were on PrEP from more than three months before becoming HIV positive. 

Of the 118 samples successfully genotyped, 44% had at least one HIV drug resistance mutation. Most of the resistance mutations were unrelated to PrEP use; that is, they had originated from antiretroviral therapy in the partner who transmitted HIV. Only one-fifth of the samples had mutations associated with the drugs used for PrEP, with the majority (23 of 27 cases) due to the emtricitabine/FTC mutation, M184I/V. There were only four cases of tenofovir-resistant HIV. Fortunately, recent studies have shown that HIV with the M184V/I mutations and/or tenofovir-associated mutations can be effectively treated with widely available combinations of antiretroviral drugs that are in the form of one pill taken daily. 

“Taking PrEP every day is very effective at preventing HIV,” Dr Urvi Parikh, Associate Professor of Medicine at the University of Pittsburgh and Co-Director of the GEMS study, said. “The number of reported infections on PrEP was very small compared to the number of PrEP users, which tells us that the benefit of PrEP in preventing HIV far outweighs the risk of drug resistance.” Continued monitoring for drug resistance with PrEP rollout will be important for the long-term success of both treatment and prevention programmes. 

Jul. 19, 2021

The ICASA Hybrid satellite symposium in 2021 will offer satellite holders the occasion to present their research and share knowledge with over 10,000 expected attendees both on-site and through our virtual satellite platform. Several online tools have been introduced to make this hybrid interaction enjoyable for both delegates and satellite holders.

In-Person Session
For additional information about our Hybrid satellite symposium:
Please visit our website:
Please contact us via email at: or by Phone or WhatsApp: +233(0)555692455
Jul. 19, 2021

ICASA 2021 Satellite symposium booking is ongoing and ends on 31st August 2021. Make your booking as soon as possible and get the best slot